Keywords: important, xoma, activities, relating, its, neuprex, rbpi-23

1994: AN IMPORTANT YEAR FOR XOMA?

Article | 02 May 1994

Print This

Xoma's activities in 1994 relating to its Neuprex (rBPI-23) sepsis product should bring the company back into the forefront of investors' ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in